|
|
|
|
|
|
|
19.03.26 - 14:12
|
These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity (24/7 Wall St.)
|
|
|
A death cross forms when a stock's 50-day moving average crosses below its 200-day moving average, signaling a potential downtrend. Right now, Bristol Myers Squibb (NYSE: BMY), FedEx (NYSE: FDX), and Ralph Lauren (NYSE: RL) are all flashing that signal. With the CBOE Volatility Index (VIX) at around 25, elevated macro uncertainty is clustering these ... These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity
The post These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity appeared first on 24/7 Wall St.....
|
|
|
19.03.26 - 12:00
|
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026 (Business Wire)
|
|
|
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2026 on Thursday, April 30, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.
Investors and the general public are invited to listen to a live audio webcast of the call at http://investor.bms.com. Materials related to the call will be available on the company's Investor Relations website prior to the start of the conference call.
A replay of the webcast will be available here approximately three hours after the conference call concludes.
About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and fo...
|
|
|
19.03.26 - 11:21
|
Evotec: Positive News verpuffen – Aktie fällt erneut (Der Aktionaer)
|
|
|
Auch eigentlich gute Meldungen prallen bei der Aktie von Evotec derzeit einfach ab. Beim Wirkstoffforscher Evotec klingelt die Kasse: Das Unternehmen erhält erneut eine Meilensteinzahlung vom US-Pharmakonzern Bristol Myers Squibb (BMS). Die Aktie verliert trotzdem heute erneut mehr als drei Prozent....
|
|
|
|
|
|
|
19.03.26 - 09:45
|
Evotec-Aktie: Diese News will keiner mehr lesen (Sharedeals)
|
|
|
Die jüngste Nachricht des Hamburger Wirkstoffforschers Evotec liefert auf den ersten Blick einen positiven Impuls: Im Rahmen der Kooperation mit Bristol Myers Squibb erhält das Unternehmen mal wieder eine Meilensteinzahlung – diesmal in Höhe von überschaubaren 10 Millionen US-Dollar durch den Start einer klinischen Phase-1-Studie mit dem Wirkstoffkandidaten BMS-986506 zur Behandlung von fortgeschrittenem Nierenzellkarzinom. Die […]
The post Evotec-Aktie: Diese News will keiner mehr lesen first appeared on sharedeals.de....
|
|
|
|
|
|
|
19.03.26 - 07:33
|
Corporate News: Evotec SE (EQS)
|
|
|
Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein‑Degradation‑Partnerschaft nach Start einer klinischen Studie...
|
|
|
|
|
|
|
|
|
|
|
12.03.26 - 21:36
|
Colgate-Palmolive Announces Quarterly Dividend Increase and Elects Christopher Boerner, Ph.D. to Board of Directors (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--The Board of Directors of Colgate-Palmolive Company (NYSE:CL) today announced an increase in the quarterly common stock cash dividend to $0.53 up from $0.52 per share. The increase will be effective in the second quarter, 2026. The Board declared that the second quarter dividend is to be paid on May 15, 2026, to shareholders of record on April 20, 2026. On an annualized basis, the new dividend rate is $2.12 versus $2.08 per share previously. The Company has paid uninterrupted dividends on its common stock since 1895.
Separately, the Company also announced today that Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer of Bristol-Myers Squibb Company (“Bristol Myers Squibb”), has been elected to Colgate-Palmolive's Board of Directors effective March 15, 2026.
Dr. Boerner, 55, has served as Chief Executive Officer of Bristol Myers Squibb, a global biopharmaceutical company, since November 2023 and as Board Chair since April 2024 and will bring extensive global ...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
